P. Bostrom

发表

Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor.

P. Warde, Philippe Bédard, A. Hansen, 2020, European urology oncology.

A new and highly prognostic system to discern T1 bladder cancer substage.

T. H. van der Kwast, A. Zlotta, N. Fleshner, 2012, European urology.

Staging and Staging Errors in Bladder Cancer

A. Zlotta, A. Finelli, N. Fleshner, 2010 .

Prognostic value of molecular markers, sub‐stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer

T. H. van der Kwast, A. Zlotta, E. Zwarthoff, 2012, BJU international.

Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin

S. Rorive, A. Zlotta, S. Shariat, 2011, Urology annals.

Risk factors associated with positive surgical margins’ location at radical cystectomy and their impact on bladder cancer survival

T. H. van der Kwast, Y. Lotan, Y. Allory, 2021, World Journal of Urology.

Secondary cancer after radiotherapy for prostate cancer: should we be more aware of the risk?

M. Soloway, P. Bostrom, 2007, European urology.

Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.

A. Evans, T. H. van der Kwast, Z. Cohen, 2013, European urology.

FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†.

T. H. van der Kwast, N. Malats, M. Márquez, 2020, European urology.

Does patient age affect survival after radical cystectomy?

A. Zlotta, A. Finelli, N. Fleshner, 2012, BJU international.

FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer

B. Gallie, A. Zlotta, N. Fleshner, 2014, Virchows Archiv.

Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients

A. Broeks, Y. Lotan, Y. Allory, 2021, Urologic Oncology: Seminars and Original Investigations.

Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.

T. H. van der Kwast, R. Bristow, P. Warde, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

T. H. van der Kwast, S. Culine, A. Broeks, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

The FGFR3 mutation is related to favorable pT1 bladder cancer.

T. H. van der Kwast, A. Zlotta, E. Zwarthoff, 2009, The Journal of urology.

Gut microbiota signatures associate with prostate cancer risk

L. Elo, P. Taimen, P. Boström, 2021, medRxiv.

Upper urinary tract cancer--challenges for the urologist.

M. Soloway, P. Bostrom, 2007, The Journal of urology.

External validation of a biomarker based pre-cystectomy algorithm to predict nonorgan confined urothelial cancers.

A. Zlotta, N. Fleshner, D. Margel, 2012, The Journal of urology.

Bladder cancer after radiotherapy for prostate cancer: detailed analysis of pathological features and outcome after radical cystectomy.

M. Soloway, S. Samavedi, M. Manoharan, 2008, The Journal of urology.

Point-of-care clinical documentation: assessment of a bladder cancer informatics tool (eCancerCareBladder): a randomized controlled study of efficacy, efficiency and user friendliness compared with standard electronic medical records

Raymond Chow, Kelly Lane, Justin Liu, 2011, J. Am. Medical Informatics Assoc..

European Association of Urology (@Uroweb) recommendations on the appropriate use of social media.

Todd M Morgan, Alexander Kutikov, Morgan Rouprêt, 2014, European urology.

Imaging renal cell carcinoma with ultrasonography, CT and MRI

N. Lawrentschuk, A. Finelli, M. Leveridge, 2010, Nature Reviews Urology.

Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols

A. Zlotta, A. Finelli, N. Fleshner, 2013, World Journal of Urology.

Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi‐institutional study

A. Evans, T. H. van der Kwast, E. Messing, 2011, BJU international.

Update on novel imaging techniques for the detection of lymph node metastases in bladder cancer.

I. Jambor, P. Bostrom, A. Salminen, 2016, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

793 A multidisciplinary bladder cancer clinic delivers personalized care for complex bladder cancer patients

R. Bristow, T. Hermanns, N. Fleshner, 2014 .

Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy

Y. Lotan, Y. Allory, F. Radvanyi, 2023, BJU international.

Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome

Antonio Finelli, Tuomas Mirtti, A. Zlotta, 2012, BJU international.

Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).

B. Helfand, M. Preston, D. Somford, 2023, European urology.